Hinge Bio
Clinical trials sponsored by Hinge Bio, explained in plain language.
-
New antibody aims to tame lupus by targeting troublemaking cells
Disease control Recruiting nowThis early-stage study tests a new drug called HB2198 in 30 adults with moderate to severe lupus, including kidney inflammation. The drug is designed to temporarily remove certain immune cells (B cells) that drive the disease. Participants receive two doses and are monitored for …
Phase: PHASE1 • Sponsor: Hinge Bio • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New Dual-Target antibody tested for safety in humans
Knowledge-focused Recruiting nowThis early-phase trial tests the safety of a single dose of HB2198, an experimental antibody that binds to two immune cell targets (CD19 and CD20). About 32 healthy adults will receive either the drug or a placebo and be monitored for about two months. The goal is to see if the d…
Phase: PHASE1 • Sponsor: Hinge Bio • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:06 UTC